Factors influencing the systolic blood pressure response to drug therapy

Journal of Clinical Hypertension

Volumn 4, Issue 1, 2002, Pages 35-40

  Campo, Carlos ^a   Segura, Julián ^a   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; URIC ACID;

AGE; AGED; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; ELDERLY CARE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MORTALITY; NEGRO; PROGNOSIS; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TARGET ORGAN;

EID: 0036175651     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2002.00487.x     Document Type: Review

References (59)

1. Systolic versus diastolic blood pressure and risk of coronary heart disease: Framingham Study
2. The paradigm has shifted to systolic blood pressure
3. Hemodynamic patterns of age-related changes in blood pressure: The Framingham Heart Study
4. Identification and management of stroke risk in older people: A national survey of current practice in primary care
5. Awareness, treatment and control of systolic blood pressure in the United States
6. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
7. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
8. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension in China
9. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
10. STOP-Hypertension 2: A prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension Swedish Trial in Old Patients with Hypertension
11. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging
12. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study
13. Pretreatment blood pressure as a predictor of 21-year mortality
14. Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials
15. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results
16. The natural history of borderline isolated systolic hypertension
17. National High Blood Pressure Education Program working group report on hypertension in the elderly
18. Hypertension and borderline isolated systolic hypertension increase risks of CVD and mortality in male physicians
19. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
20. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged difference in blood pressure prospective observational studies corrected for the regression dilution bias
21. Influence of hypotensive drug treatment in elderly hypertensives: Study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly (EWPHE)
22. A meta-analysis of outcome trials in elderly patients
23. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Project (CAPPP) randomised trial
24. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
25. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
26. Randomised trial of effects of calcium antagonist compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
27. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
28. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study
29. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
30. Treatment of mild hypertension study (TOMHS): Final results
31. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
32. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: Field trial in general practice
33. Prospective comparison of four antihypertensive agents in daily clinical practice
34. A comparison of four primary classes of antihypertensive monotherapy in Thai patients
35. Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension
36. ACE inhibitors, beta blockers, calcium channel blockers and diuretics in systolic hypertension control
37. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: Results of a randomized trial in Johannesburg, South Africa
38. World Health Organization-International Society of Hypertension guidelines for the management of hypertension
39. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
40. Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations
41. How can hypertensive patients be treated? The contribution of combined therapy
42. The heterogeneity of hypertension: Why doesn't every patient respond to every antihypertensive drug
43. Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations
44. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug
45. Renin system activity as a determinant of response to treatment of hypertension and heart failure
46. Clinical parameters in essential hypertensive patients
47. Predictors of number of drugs needed to control blood pressure in essential hypertension
48. Influence of diabetes and type of hypertension on response to antihypertensive treatment
49. Predictors of systolic blood pressure control with antihypertensive monotherapy
50. Factors predictive of attendance at clinic and blood pressure control in hypertensive patients
51. Blood pressure control in a hypertension clinic
52. Contemporary management of refractory hypertension
53. Sodium and potassium intake influence therapeutic needing in essential hypertension
54. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II
55. Physiological aspects of primary hypertension
56. The emerging concept of vascular remodeling
57. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor
58. Effects of antihypertensive therapy on hypertensive vascular disease
59. Clinical features, anthropometric characteristics, and racial influences on the "white-coat effect" in a single-center cohort of 1553 consecutive subjects undergoing ambulatory blood pressure monitoring